Effect of Acid Suppression on Molecular Predictors for Esophageal Cancer

Pierre Lao-Sirieix,1 Amanda Roy,2 Claire Worrall,1 Sarah L. Vowler,3 Sue Gardiner,1 and Rebecca C. Fitzgerald1

1Medical Research Council Cancer Cell Unit, Hutchison-Medical Research Council Research Centre; ‘G1 Physiology Unit, University College Hospital, London, United Kingdom and 3Centre for Applied Medical Statistics, Department of Public Health and Primary Care, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom

Abstract

Background: Gastroesophageal reflux disease is a risk factor for the development of Barrett’s esophagus and esophageal adenocarcinoma. The effect of antireflux therapy on the incidence of esophageal adenocarcinoma is unknown. Acid exposure in vitro induces hyperproliferation via a cyclooxygenase-2 (COX-2) dependent mechanism. Epidemiologic and animal studies suggest that COX inhibitors decrease the incidence of esophageal adenocarcinoma.

Aim: To study the differential effect of complete compared with incomplete acid suppression on proliferation, apoptosis, and COX-2.

Patients and Methods: Fifty-one patients with Barrett’s esophagus who underwent pH monitoring were divided into two groups according to their DeMeester score: 32 acid-suppressed patients (group 1) and 19 patients with abnormally high acid exposure (group 2). Slides from biopsies taken 3 months before and 4 and 12 months after pH monitoring were stained for Mcm2, COX-2, c-myc, and cleaved caspase-3 (marker of apoptosis).

Results: There was no evidence of a difference between the two groups in terms of age, gender ratio, medication, dysplasia status, and the expression levels of any marker before pH monitoring. In group 1, Mcm2 expression decreased in the luminal surface and throughout the tissue 12 months after monitoring when compared with the two previous time points (P < 0.05). The levels of COX-2 increased overtime (P < 0.01 in group 1, not significant in group 2). There was no correlation between Mcm2 and COX-2 expression. Acid suppression had no effect on c-myc or apoptosis.

Conclusion: Long-term acid suppression reduces proliferation in Barrett’s esophagus samples but has no advantageous effect on c-myc, apoptosis, or COX-2. (Cancer Epidemiol Biomarkers Prev 2006;15(2):288–93)

Introduction

The incidence of esophageal adenocarcinoma has increased dramatically in the west in the last 30 years (1). Esophageal adenocarcinoma generally arises from a premalignant metaplastic columnar epithelium which replaces the distal native squamous epithelium, called Barrett’s esophagus (2). A long history of gastroesophageal reflux disease has been shown to be an independent risk factor for the development of esophageal adenocarcinoma (3) and Barrett’s esophagus (4) and the duration of the reflux episodes correlated with the length of the Barrett’s esophagus segment (5). The apparent role for gastroesophageal reflux disease in the development of esophageal adenocarcinoma and Barrett’s esophagus has triggered the search for chemopreventive strategies, which involve the complete eradication of gastroesophageal reflux.

Both surgical and antireflux therapies lead to a partial endoscopic regression of Barrett’s esophagus, the appearance of squamous islands (6, 7), and a decrease in the incidence of dysplasia (7-9). Despite the evidence for some endoscopic and histopathologic improvement, these therapies rarely result in the complete eradication of the Barrett’s segment (10). Some individual studies have shown a small reduction in cancer incidence in patients treated with surgical, compared with medical, antireflux therapies (11-13). However, a meta-analysis by Corey et al. (14) did not show any statistical significance between the two treatments. It should be noted that these studies lacked a control group because all patients had some form of acid suppression treatment.

This apparently contradictory evidence may result from the nonstandardization of the types and doses of acid suppressants used, as well as the variation in surgical procedures. Furthermore, in these studies, the efficacy of the antireflux treatment was generally inferred from the self-reported reflux symptomatology. However, it is clear from several independent investigations that symptom control does not always concord with complete intraesophageal pH normalization (7, 15, 16). Normalization of acid reflux may be important in view of laboratory evidence, which suggests that pulsatile reflux exposure might alter the cell kinetics in favor of malignant progression. Specifically, pulsatile acid exposure of Barrett’s esophagus using ex vivo and in vitro model systems has been shown to increase cell proliferation and reduce apoptosis via activation of mitogen-activated protein kinase pathways (17-19). In a subsequent clinical study, which attempted to control for the amount of reflux exposure, Ouatu-Lascar et al. (16) showed that complete acid normalization with lansoprazole treatment decreased the proliferative index in Barrett’s esophagus patients, as measured by proliferating cell nuclear antigen expression. In the same year, an independent group showed that although complete normalization with omeprazole had no effect on proliferation, incomplete normalization with ranitidine led to an increased proliferation (6). These results were further supported by a surgical series in which incompletely acid-suppressed patients had an increased epithelial proliferation rate (20).

As well as acid containing refluxate, bile reflux has also been shown to occur frequently in Barrett’s esophagus patients (21). In vitro and ex vivo data have shown that acidified bile induced...
c-myc expression (22) and caused hyperproliferation via cyclooxygenase-2 (COX-2) and protein kinase C (23). On the other hand, inhibition of COX-2 or protein kinase C led to a decrease in proliferation in ex vivo cultures of Barrett’s explants and in vitro adenocarcinoma cell cultures (18, 24). Furthermore, in retrospective, epidemiologic studies of non-steroidal anti-inflammatory drugs were shown to reduce the risk of progression to esophageal adenocarcinoma (25, 26).

Animal models of duodenogastroesophageal reflux have also suggested that COX-2 inhibitors might decrease the risk of esophageal adenocarcinoma arising within Barrett’s esophagus (27-29). Further to this work, a chemoprevention trial, called Aspirin Esomeprazole Chemoprevention Trial, is in progress to study the effect of high-dose versus low-dose proton pump inhibitor therapy with or without aspirin on the risk of cancer progression in a large prospective male cohort over 8 years (http://www.digestivediseases.org/news.shtml).

Using esophageal adenocarcinoma as the end point for chemoprevention trials is ideal; however, there are a number of practical difficulties with this approach in view of the large study size and the long follow-up period required. Therefore, the use of surrogate markers for cancer progression is a useful adjunct to the definitive studies. In addition, biomarker studies may also provide mechanistic information about the molecular basis for cancer progression which may enable a more targeted approach to chemopreventive therapies in the future (for review, see ref. 30). In the hunt for markers of progression to esophageal adenocarcinoma, a number of targets have been identified. Many of these, including alterations in the expression of p16, p53, and cyclin D1 and surface expression of minichromosome maintenance protein (Mcm) 2, can be linked to cell cycle progression (31-33). Until recently, assessment of cell proliferation on fixed tissue (Mcm) 2, can be linked to cell cycle progression (31-33). Until recently, assessment of cell proliferation on fixed tissue has relied on markers with disadvantages, such as Ki-67 and proliferating cell nuclear antigen (PCNA), which are subject to controversy, and proliferating cell nuclear antigen expression profile has recently, assessment of cell proliferation on fixed tissue has been linked to cell cycle progression (31-33).

The role of Ki-67 is still not worked out and its expression profile has been described (31, 39). Cleaved caspase-3 and c-myc expression in the epithelial explants and Barrett’s explants and in vitro adenocarcinoma arising within Barrett’s esophagus (27-29). Further to this work, a chemoprevention trial, called Aspirin Esomeprazole Chemoprevention Trial, is in progress to study the effect of high-dose versus low-dose proton pump inhibitor therapy with or without aspirin on the risk of cancer progression in a large prospective male cohort over 8 years (http://www.digestivediseases.org/news.shtml).

Using esophageal adenocarcinoma as the end point for chemoprevention trials is ideal; however, there are a number of practical difficulties with this approach in view of the large study size and the long follow-up period required. Therefore, the use of surrogate markers for cancer progression is a useful adjunct to the definitive studies. In addition, biomarker studies may also provide mechanistic information about the molecular basis for cancer progression which may enable a more targeted approach to chemopreventive therapies in the future (for review, see ref. 30). In the hunt for markers of progression to esophageal adenocarcinoma, a number of targets have been identified. Many of these, including alterations in the expression of p16, p53, and cyclin D1 and surface expression of minichromosome maintenance protein (Mcm) 2, can be linked to cell cycle progression (31-33). Until recently, assessment of cell proliferation on fixed tissue has relied on markers with disadvantages, such as Ki-67 and proliferating cell nuclear antigen (PCNA), which are subject to controversy, and proliferating cell nuclear antigen expression profile has been described (31, 39). Cleaved caspase-3 and c-myc expression in the epithelial explants and Barrett’s explants and in vitro adenocarcinoma arising within Barrett’s esophagus (27-29).

The role of Ki-67 is still not worked out and its expression profile has been described (31, 39). Cleaved caspase-3 and c-myc expression in the epithelial explants and Barrett’s explants and in vitro adenocarcinoma arising within Barrett’s esophagus (27-29). Further to this work, a chemoprevention trial, called Aspirin Esomeprazole Chemoprevention Trial, is in progress to study the effect of high-dose versus low-dose proton pump inhibitor therapy with or without aspirin on the risk of cancer progression in a large prospective male cohort over 8 years (http://www.digestivediseases.org/news.shtml).

Using esophageal adenocarcinoma as the end point for chemoprevention trials is ideal; however, there are a number of practical difficulties with this approach in view of the large study size and the long follow-up period required. Therefore, the use of surrogate markers for cancer progression is a useful adjunct to the definitive studies. In addition, biomarker studies may also provide mechanistic information about the molecular basis for cancer progression which may enable a more targeted approach to chemopreventive therapies in the future (for review, see ref. 30). In the hunt for markers of progression to esophageal adenocarcinoma, a number of targets have been identified. Many of these, including alterations in the expression of p16, p53, and cyclin D1 and surface expression of minichromosome maintenance protein (Mcm) 2, can be linked to cell cycle progression (31-33). Until recently, assessment of cell proliferation on fixed tissue has relied on markers with disadvantages, such as Ki-67 and proliferating cell nuclear antigen (PCNA), which are subject to controversy, and proliferating cell nuclear antigen expression profile has been described (31, 39). Cleaved caspase-3 and c-myc expression in the epithelial explants and Barrett’s explants and in vitro adenocarcinoma arising within Barrett’s esophagus (27-29).

The role of Ki-67 is still not worked out and its expression profile has been described (31, 39). Cleaved caspase-3 and c-myc expression in the epithelial explants and Barrett’s explants and in vitro adenocarcinoma arising within Barrett’s esophagus (27-29). Further to this work, a chemoprevention trial, called Aspirin Esomeprazole Chemoprevention Trial, is in progress to study the effect of high-dose versus low-dose proton pump inhibitor therapy with or without aspirin on the risk of cancer progression in a large prospective male cohort over 8 years (http://www.digestivediseases.org/news.shtml).

Using esophageal adenocarcinoma as the end point for chemoprevention trials is ideal; however, there are a number of practical difficulties with this approach in view of the large study size and the long follow-up period required. Therefore, the use of surrogate markers for cancer progression is a useful adjunct to the definitive studies. In addition, biomarker studies may also provide mechanistic information about the molecular basis for cancer progression which may enable a more targeted approach to chemopreventive therapies in the future (for review, see ref. 30). In the hunt for markers of progression to esophageal adenocarcinoma, a number of targets have been identified. Many of these, including alterations in the expression of p16, p53, and cyclin D1 and surface expression of minichromosome maintenance protein (Mcm) 2, can be linked to cell cycle progression (31-33). Until recently, assessment of cell proliferation on fixed tissue has relied on markers with disadvantages, such as Ki-67 and proliferating cell nuclear antigen (PCNA), which are subject to controversy, and proliferating cell nuclear antigen expression profile has been described (31, 39). Cleaved caspase-3 and c-myc expression in the epithelial explants and Barrett’s explants and in vitro adenocarcinoma arising within Barrett’s esophagus (27-29)
was analyzed by \( \chi^2 \) test. The Marginal Homogeneity test was used to test for differences in the degree of dysplasia between the groups and over time within the groups. The Friedman’s test was used for comparing continuous variables between the two groups and looking at the values of the markers over time. Analysis of correlation of expression of markers was done with a Spearman’s correlation test. In all cases, \( P < 0.05 \) was required for significance. Analysis was carried out with SPSS V12.0 (SPSS, Inc., Chicago, IL) and Stat-Xact V4.0 (Cytel Corporation, Cambridge, MA).

Results

Patient Demographics. The patients were divided into two groups according to their intraoesophageal acid exposure as measured by the DeMeester score (Table 1). Group 1 was composed of 33 patients with a normal acid exposure and group 2 was composed of 19 patients with an abnormally high acid exposure. The two groups did not differ in terms of age, gender ratio, length of Barrett’s esophagus segment, medication levels, and degree of dysplasia before pH monitoring (Table 1). There was also no evidence of a difference in the symptomatology between the two groups although, as expected, the group with abnormal acid exposure had a greater preponderance of reflux symptoms (25% of group 1 versus 47% of group 2). The manometric characteristics of the two groups were not statistically different but group 2 had a higher percentage of patients with a hypotcontracting esophagus than group 1 (79% versus 41%, respectively). This manometric abnormality would be in keeping with the higher percentage of patients with a hypocontracting manometric abnormality would be in keeping with the higher esophagus than group 1 (79% versus 41%, respectively). This manometric abnormality would be in keeping with the higher proportion of group 2 patients with reflux symptoms. Over the follow-up period, the degree of dysplasia showed no evidence of varying over time in either of the two groups.

Table 1. Patient demographics, medication, symptoms, manometry, and degree of dysplasia from the retrospective cohort

<table>
<thead>
<tr>
<th>Group</th>
<th>No. patients</th>
<th>DeMeester score</th>
<th>Age at pH monitoring (y)</th>
<th>Gender ratio (male/female)</th>
<th>Length of Barrett’s esophagus segment (cm)</th>
<th>Medication</th>
<th>Symptoms</th>
<th>Manometry</th>
<th>Dysplasia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group 1</td>
<td>33</td>
<td>4.4 ± 0.6</td>
<td>61.0 ± 1.5</td>
<td>3.16:1</td>
<td>4.1 ± 0.4</td>
<td>53 (1%)</td>
<td>19 (58%)</td>
<td>9 (27%)</td>
<td>8 (27%)</td>
</tr>
<tr>
<td>Group 2</td>
<td>19</td>
<td>59.8 ± 7.8</td>
<td>62.2 ± 2.8</td>
<td>1.71:1</td>
<td>4.7 ± 0.7</td>
<td>2 (3%)</td>
<td>7 (21%)</td>
<td>10 (30%)</td>
<td>8 (27%)</td>
</tr>
</tbody>
</table>

Discussion

In this retrospective study, we have analyzed the link between acid suppression, proliferation (c-myc and Mcm2), COX-2, and apoptosis (cleaved caspase-3). Acid-suppressed patients (group 1) were shown to have a decrease in Mcm2 expression over time whereas COX-2 protein levels increased over the same time scale (Figs. 1 and 2). These statistically significant changes in expression were not seen in patients with abnormal pH monitoring. The expression levels of cleaved caspase-3, a marker of apoptosis, and c-myc were not affected by acid suppression.

In this patient cohort, 37% of patients in group 2 were asymptomatic but not acid suppressed and 25% of group 1 patients had reflux symptoms despite adequate acid suppression. This is in agreement with previous work which has shown that symptom control does not equate with adequate acid suppression (16, 42). Eighteen percent (9 of 51) of patients in our cohort were not adequately acid suppressed despite being on supraphysiologic doses of proton pump inhibitors. This is in keeping with 20% patients reported to be unresponsive to therapeutic doses of proton pump inhibitor in the literature (43). This phenomenon may be explained by an individual variation in the expression of Mcm2 and COX-2 with a biopsy (Fig. 4).

c-Myc and Cleaved Caspase-3 Expression. For both c-myc (Fig. 1) and cleaved caspase-3 (Fig. 1), similar expression levels were observed in the two groups before pH monitoring. Furthermore, no differences in expression were seen over time in any group (data not shown). The expression of c-myc was higher in dysplastic Barrett’s esophagus than in nondysplastic samples in the surface, upper crypt, and throughout the tissue (Fig. 5).

Table 1. Patient demographics, medication, symptoms, manometry, and degree of dysplasia from the retrospective cohort

<table>
<thead>
<tr>
<th>Group</th>
<th>No. patients</th>
<th>DeMeester score</th>
<th>Age at pH monitoring (y)</th>
<th>Gender ratio (male/female)</th>
<th>Length of Barrett’s esophagus segment (cm)</th>
<th>Medication</th>
<th>Symptoms</th>
<th>Manometry</th>
<th>Dysplasia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group 1</td>
<td>33</td>
<td>4.4 ± 0.6</td>
<td>61.0 ± 1.5</td>
<td>3.16:1</td>
<td>4.1 ± 0.4</td>
<td>53 (1%)</td>
<td>19 (58%)</td>
<td>9 (27%)</td>
<td>8 (27%)</td>
</tr>
<tr>
<td>Group 2</td>
<td>19</td>
<td>59.8 ± 7.8</td>
<td>62.2 ± 2.8</td>
<td>1.71:1</td>
<td>4.7 ± 0.7</td>
<td>2 (3%)</td>
<td>7 (21%)</td>
<td>10 (30%)</td>
<td>8 (27%)</td>
</tr>
</tbody>
</table>

Discussion

In this retrospective study, we have analyzed the link between acid suppression, proliferation (c-myc and Mcm2), COX-2, and apoptosis (cleaved caspase-3). Acid-suppressed patients (group 1) were shown to have a decrease in Mcm2 expression over time whereas COX-2 protein levels increased over the same time scale (Figs. 1 and 2). These statistically significant changes in expression were not seen in patients with abnormal pH monitoring. The expression levels of cleaved caspase-3, a marker of apoptosis, and c-myc were not affected by acid suppression.

In this patient cohort, 37% of patients in group 2 were asymptomatic but not acid suppressed and 25% of group 1 patients had reflux symptoms despite adequate acid suppression. This is in agreement with previous work which has shown that symptom control does not equate with adequate acid suppression (16, 42). Eighteen percent (9 of 51) of patients in our cohort were not adequately acid suppressed despite being on supraphysiologic doses of proton pump inhibitors. This is in keeping with 20% patients reported to be unresponsive to therapeutic doses of proton pump inhibitor in the literature (43). This phenomenon may be explained by an individual variation in the expression of Mcm2 and COX-2 with a biopsy (Fig. 4).

c-Myc and Cleaved Caspase-3 Expression. For both c-myc (Fig. 1) and cleaved caspase-3 (Fig. 1), similar expression levels were observed in the two groups before pH monitoring. Furthermore, no differences in expression were seen over time in any group (data not shown). The expression of c-myc was higher in dysplastic Barrett’s esophagus than in nondysplastic samples in the surface, upper crypt, and throughout the tissue (Fig. 5).
in pharmacokinetics, mainly dependent on a cytochrome P4502C19 polymorphism (reviewed in ref. 44). Furthermore, a recent study showed that in patients with persistent acid-reflux despite proton pump inhibitor therapy, altering their medication did not significantly alter intraesophageal or intragastric pH exposure (45). This may explain why the proliferation index, as measured by Mcm2, was unaltered over time for group 2 even after their medication was changed.

Figure 1. Representative sections from a negative control and immunohistochemistry for COX-2, Mcm2, cleaved caspase-3, and c-myc antibodies. Magnification, ×100 (left); ×400 (right). Square, magnified area.
increases COX-2 expression through stimulation of the CCK 2 receptor (39, 47). Previous work from our laboratory showed a similar increase although this only reached statistical significance in group 1. The reduction in cell proliferation in group 1 patients who remained acid suppressed over a 12-month period is in keeping with a previous prospective study which evaluated the effect of complete versus incomplete acid suppression on proliferating cell nuclear antigen expression over a 6-month period (46). The number of patient years in this study is too small to draw any meaningful conclusions about cancer incidence; however, three patients from group 1 developed high-grade dysplasia or esophageal adenocarcinoma over the course of the study. The significant reduction in Mcm2 observed in group 1 over time is more striking when one considers that these three high-grade dysplasia/esophageal adenocarcinoma patients, which were included in the analysis, had a higher proliferation index throughout the study and were thus likely to mask changes resulting form acid-suppression. Interestingly, the expression levels of Mcm2 at the luminal surface were statistically higher for the three progressors than for the nonprogressors even before the histopathologic diagnosis of dysplasia ($P = 0.01$; data not shown). These data are in keeping with previous work published by our laboratory where high levels of Mcm2 expression at the luminal surface correlated with later progression to cancer (31).

The expression of COX-2 increased over time in both groups although this only reached statistical significance in group 1. Previous work from our laboratory showed a similar increase of COX-2 over time in patients undergoing surveillance. The explanation may be related to induction of COX-2 by gastrin in patients taking proton pump inhibitors because gastrin increases COX-2 expression through stimulation of the CCK2 receptor (39).

Amplification of the c-myc gene has been reported in high-grade dysplasia and esophageal adenocarcinoma (48, 49) but to date, this is the first report of increased c-myc expression with the development of dysplasia. In vitro and ex vivo studies suggested that exposure to a pulse of acidified bile increased c-myc (22) and induced hyperproliferation in a COX-2-dependent fashion (23). In addition, pulsatile acid exposure has been shown to decrease apoptosis (18, 19). However, in this study, no differences were seen in any of the groups for both c-myc and cleaved caspase-3 and there was no correlation between COX-2 expression and proliferation as measured by Mcm2 expression. It is possible that the concentration of bile acid in acid reflux was insufficient to trigger a modulation of c-myc expression. In addition, results from an in vitro system cannot always be directly applied in vivo.

Acid suppression by proton pump inhibitor was shown to decrease the degree of dysplasia (6-8) and we have shown in this study that it decreases proliferation at the luminal surface. These data suggest a possible chemopreventive role for proton pump inhibitors in the context of Barrett’s esophagus–associated cancers. Furthermore, our data suggest that acid suppression may increase, rather than decrease, COX-2 expression and, hence, if inhibiting the COX enzyme system is important for cancer prevention, then a dual chemopreventive strategy may be required. Only a randomized control trial with a large number of patient years, such as the ongoing Aspirin Esomeprazole Chemoprevention Trial chemoprevention trial, will determine the role of these drugs in reducing cancer incidence.

In conclusion, we showed that long-term acid suppression reduces proliferation in Barrett’s esophagus samples but has no advantageous effect on c-myc, apoptosis, or COX-2. The results from prospective studies to test the clinical validity of proton pump inhibitors as part of a chemopreventive strategy are eagerly awaited.
Acknowledgments

We thank the patients and staff of the endoscopy department for their cooperation.

References


Effect of Acid Suppression on Molecular Predictors for Esophageal Cancer


Updated version
Access the most recent version of this article at:
http://cebp.aacrjournals.org/content/15/2/288

Cited articles
This article cites 49 articles, 13 of which you can access for free at:
http://cebp.aacrjournals.org/content/15/2/288.full#ref-list-1

Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at:
http://cebp.aacrjournals.org/content/15/2/288.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.